Best of 2024: The Economist – Why GLP-1 drugs like Ozempic are changing the world
In a world grappling with obesity and chronic disease, GLP-1 drugs like Ozempic are emerging as transformative game-changers. Initially designed for diabetes, these medications now promise breakthroughs in cardiovascular, kidney, and neurodegenerative conditions, alongside potential benefits for addiction and anti-ageing. As their reach expands and costs decrease, they hold the power to enhance billions of lives and redefine societal norms. Dive into The Economist's compelling exploration of a medical revolution, and discover how these drugs could reshape industries, economies, and our collective future.
Sign up for your early morning brew of the BizNews Insider to keep you up to speed with the content that matters. The newsletter will land in your inbox at 5:30am weekdays. Register here.
The seventh BizNews Conference, BNC#7, is to be held in Hermanus from March 11 to 13, 2025. The 2025 BizNews Conference is designed to provide an excellent opportunity for members of the BizNews community to interact directly with the keynote speakers, old (and new) friends from previous BNC events – and to interact with members of the BizNews team. Register for BNC#7 here.
From The Economist, published under licence. The original article can be found on www.economist.com
© 2024 The Economist Newspaper Limited. All rights reserved.
It's not just obesity – drugs like Ozempic will change the world
GLP-1 receptor agonists are revolutionizing health care, moving beyond diabetes and obesity to treat cardiovascular, kidney, and possibly neurodegenerative diseases. As usage expands and costs drop, these drugs promise to enhance lives globally by reducing health risks associated with obesity and addiction.
The Economist
As they become cheaper, they promise to improve billions of lives
___STEADY_PAYWALL___